Live and killed rhabdovirus-based vectors as potential hepatitis C vaccines

Virology

Volumn 292, Issue 1, 2002, Pages 24-34

  Siler, Catherine A ^a,b   McGettigan, James P ^a,b   Dietzschold, Bernhard ^b   Herrine, Steven K ^b   Dubuisson, Jean ^c   Pomerantz, Roger J ^a,b   Schnell, Matthias J ^a,b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c INSTITUT PASTEUR DE LILLE   (France)

Author keywords

CTL; Hepatitis C; Humoral response; Rabies virus; Rhabdovirus; Seroconversion; Vaccine

Indexed keywords

GLYCOPROTEIN E1; GLYCOPROTEIN E2; HEPATITIS C VACCINE; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; VIRUS GLYCOPROTEIN; VIRUS VECTOR;

ANIMAL TISSUE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; RHABDOVIRUS; SEROCONVERSION; VIRION; WESTERN BLOTTING;

HEPATITIS C VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; RABIES VIRUS; RHABDOVIRIDAE;

EID: 0036058443     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.2001.1212     Document Type: Article

References (61)

1. Gene transfer into muscle by electroporation in vivo
2. Epidemiology of hepatitis C
3. Patients with chronic hepatitis C have circulating cytotoxic T cells which recognize hepatitis C virus-encoded peptides binding to HLA-A2.1 molecules
4. Generation of bovine respiratory syncytial virus (BRSV) from cDNA: BRSV NS2 is not essential for virus replication in tissue culture, and the human RSV leader region acts as a functional BRSV genome promoter
5. Vaccination of chimpanzees against infection by the hepatitis C virus
6. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome
7. Molecular virology of hepatitis C virus
8. A retention signal necessary and sufficient for endoplasmic reticulum localization maps to the transmembrane domain of hepatitis C virus glycoprotein E2
9. Charged residues in the transmembrane domains of hepatitis C virus glycoproteins play a major role in the processing, subcellular localization, and assembly of these envelope proteins
10. Chemical and immunological analysis of the rabies soluble glycoprotein
11. Folding, assembly and subcellular localization of hepatitis C virus glycoproteins
12. Formation and intracellular localization of hepatitis C virus envelope glycoprotein complexes expressed by recombinant vaccinia and Sindbis viruses
13. Hepatitis C virus glycoprotein complex localization in the endoplasmic reticulum involves a determinant for retention and not retrieval
14. Lack of protective immunity against reinfection with hepatitis C virus
15. Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization
16. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies
17. Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein
18. Virus promoters determine interference by defective RNAs: Selective amplification of mini-RNA vectors and rescue from cDNA by a 3′ copy-back ambisense rabies virus
19. Functional characterization of intracellular and secreted forms of a truncated hepatitis C virus E2 glycoprotein
20. Characterization of hepatitis C virus E2 glycoprotein interaction with a putative cellular receptor, CD81
21. A recombinant rabies virus expressing vesicular stomatitis virus glycoprotein fails to protect against rabies virus infection
22. Vaccination of chimpanzees with plasmid DNA encoding the hepatitis C virus (HCV) envelope E2 protein modified the infection after challenge with homologous monoclonal HCV
23. Hepatitis C virus lacking the hypervariable region 1 of the second envelope protein is infectious and causes acute resolving or persistent infection in chimpanzees
24. Therapy of hepatitis C
25. Selection of RNA replicons capable of persistent noncytopathic replication in mammalian cells
26. Immune responses to hepatitis C virus structural and non-structural proteins induced by plasmid DNA immunizations
27. Expression and identification of hepatitis C virus polyprotein cleavage products
28. Association of hepatitis C virus-specific CD81 T cells with viral clearance in acute hepatitis C
29. DNA vaccine strategies for hepatitis C
30. Humoral immune response to hypervariable region 1 of the putative envelope glycoprotein (gp70) of hepatitis C virus
31. Influence of antibodies to the hypervariable region of E2/NS1 glycoprotein on the selective replication of hepatitis C virus in chimpanzees
32. Effect of immune globulin on the prevention of experimental hepatitis C virus infection
33. A common structural core in the internal ribosome entry sites of picornavirus, hepatitis C virus, and pestivirus
34. Lymphoproliferative responses to hepatitis C virus core, E1, E2, and NS3 in patients with chronic hepatitis C infection treated with interferon alfa
35. Antibody to hepatitis C virus second envelope (HCV-E2) glycoprotein: A new marker of HCV infection closely associated with viremia
36. Pathogenesis, natural history, treatment, and prevention of hepatitis C
37. Mutations in hepatitis C virus RNAs conferring cell culture adaptation
38. Long-term follow-up of chimpanzees inoculated with the first infectious clone for hepatitis C virus
39. Induction of antibodies against structural proteins of hepatitis C virus in mice using recombinant adenovirus
40. Rabies virus-based vectors expressing human immunodeficiency virus type 1 (HIV-1) envelope protein induce a strong, cross-reactive cytotoxic T-lymphocyte response against envelope proteins from different HIV-1 isolates
41. Expression and immunogenicity of human immunodeficiency virus type I Gag expressed by a replication-competent rhabdovirus-based vaccine vector
42. Specific infection of CD4+ target cells by recombinant rabies virus
43. A CXCR4/CD4 pseudotype rhabdovirus that selectively infects HIV-1 envelope protein-expressing cells
44. Highly stable expression of a foreign gene from rabies virus vectors
45. Characterization of truncated forms of hepatitis C virus glycoproteins
46. DNA prime-canarypox boost with polycistronic hepatitis C virus (HCV) genes generates potent immune responses to HCV structural and nonstructural proteins
47. Binding of hepatitis C virus to CD81
48. Immunity in hepatitis C infection
49. Significance of the anti-E2 response in self-limited and chronic hepatitis C virus infections in chimpanzees and in humans
50. Molecular characterization of hepatitis C virus
51. Rhabdovirus genomes and their products
52. Plasmid DNA-based immunization for hepatitis C virus structural proteins: Immune responses in mice
53. Recombinant rabies virus as potential live-viral vaccines for HIV-1
54. Infectious rabies viruses from cloned cDNA
55. Neutralizing antibodies against hepatitis C virus and the emergence of neutralization escape mutant viruses
56. A proposed system for the nomenclature of hepatitis C viral genotypes
57. Enhancement of immunoglobulin G2a and cytotoxic T-lymphocyte responses by a booster immunization with recombinant hepatitis C virus E2 protein in E2 DNA-primed mice
58. Use of conventional or replicating nucleic acid-based vaccines and recombinant Semliki Forest derived particles for the induction of immune responses against hepatitis C virus core and E2 antigens
59. Variable and hypervariable domains are found in the regions of HCV corresponding to the flavivirus envelope and NS1 proteins and the pestivirus envelope glycoproteins
60. Evidence for immune selection of hepatitis C virus (HCV) putative envelope glycoprotein variants: Potential role in chronic HCV infections
61. Evidence for immune selection of hepatitis C virus (HCV) putative envelope glycoprotein variants: Potential role in chronic HCV infections